# GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma

> **NCT02499003** · PHASE2 · COMPLETED · sponsor: **Johannes Gutenberg University Mainz** · enrollment: 70 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Obinutuzumab and Pixantrone

## Key facts

- **NCT ID:** NCT02499003
- **Lead sponsor:** Johannes Gutenberg University Mainz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-14
- **Primary completion:** 2019-01-02
- **Final completion:** 2022-01-02
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2022-03-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02499003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02499003, "GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02499003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*